Replies to post #1954 on BioNeutral Group Inc. (fka BONU)

[MarqueeGemFinder]

With respect to your DD on BONU-Barnabas Health Collaboration :

Im of the opinion that the push to hospitals is the key piece to their sales strategy that will propel this to Sterlings .03+ valuation in the coming months. : As you alerted me yesterday-- I conducted more DD on BONU trials and potential standard implementations in hospitals and medical offices. The ability to prove excellent trial and testing results is critical for these huge contracts. Well done malt66.

This collaboration Agreement was an excellent find - but there are DEFINITELY more. Lets look for them- as we do- I will continue to sticky this.

BONU has turned the corner and she's is mighty and steady. Two major buying days and several a more on the near horizon as we close out the trips. To score trips in BONU on average-- with what appears to be on the horizon here real soon- is going to be very rewarding. A few posters said it best- someone bought 25mil at .0005. That person(s) is going to be rich. Tis stock will soar on news that many of us seemingly expect --- dilution was a necessity. The capital has been raised. I for one, am very very excited for BONU. By Christmas- we will only be talking about how high she will go.

Here is the Barnabas Health - BONU collaboration Agreement : indications of huge sales contracts potential with test results expected to be published soon
click here: BONU and BARNABAS ---COLLABORATION AGREEMENT

[stervc]

About this BONU & St. Barnabas Collaborative Agreement…

I am very confident that the investing community really don’t understand the magnitude of just how big it is that BONU has a Collaboration Agreement with a multi-billion dollar company; the Saint Barnabas Corporation. The Saint Barnabas Corporation is under the umbrella of medical centers of Barnabas Health.
http://www.hoovers.com/company-information/cs/company-profile.Saint_Barnabas_Corporation.7183c0bcf7250755.html

The Collaboration Agreement between BONU and Barnabas Health was brought to the forum below courtesy of malt66 as indicated below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94509371
http://www.lawinsider.com/contracts/1n1BmTZzv5TR9hmsL3qdQF/bioneutral-group-inc/new-jersey/2012-01-25

Barnabas Health has annual revenues of $2.4 Billion… 18,200 Employees… 4,600 Physicians and much more that can be seen from viewing the company’s Vital Statistics below:

http://www.barnabashealth.org/about/index3.html#top


As we all can very clearly see, Barnabas Health is very credible. This is important because it was Barnabas Health that confirmed that BONU products are very real and legit as confirmed within the 10-K that was filed with the SEC by BONU confirming the Collaboration Agreement and the results presented by Barnabas Health. Make sure to read all that is below from the 10-K showing this confirmation and more:

http://www.sec.gov/Archives/edgar/data/1427030/000121390013000399/f10k2012_bioneutral.htm
On January 18, 2012 the Company entered into a Collaborative Agreement (the " Collaborative Agreement") with Saint Barnabas Corporation, a not for profit corporation organized under the laws of the state of New Jersey ("Barnabas Health"). Pursuant to the Collaborative Agreement, the parties agreed to develop protocols for the testing of our Ygiene® 206. The parties further agreed that Barnabas Health shall assist and collaborate with the Company in testing new sporicidal formulations and applications of Ygiene® 206. All test results and reports will be provided to the Company by Barnabas Health. In addition, the Collaborative Agreement provides that Barnabas Health shall have the first right to publish in medical or academic journals the results of the testing and evaluation of Ygiene® 206, subject to certain conditions set forth in the Collaborative Agreement. Further, the Company and Barnabas Health have agreed to a division of revenue earned from the use or sale of Ygiene® 206, as set forth in the Collaborative Agreement. All intellectual property rights relating to Ygiene® 206, and any developments, formulations, uses, applications, enhancements, discoveries, inventions and improvements pertaining thereto, including all uses thereof, shall remain the exclusive property of the Company.

The Company and Barnabas Health of West Orange, New Jersey, released the results of an initial collaborative research program. In this study of about fifty (50) surgical instruments conducted at Saint Barnabas Medical Center, a Barnabas Health facility, Ygiene 206 Sterilant was shown to effectively remove microorganisms in the presence of blood from contaminated surgical instruments in 90 seconds to two minutes. This use of Ygiene would represent an important preventive step in the reduction of serious occupational exposure to healthcare workers of blood or bodily fluids from surgical instruments. …

… Dr. Andy Kielbania, ICEO of BioNeutral Group advised that, "A clinical test at Barnabas Health commenced April 3rd. We expect results in 45 days. A confirmed positive result would help position Ygiene 206 in its first significant commercial application."…

…On April 4, 2012 the Company announced positive results of a series of tests performed by Dr. Philip Tierno with respect to the use of Ygiene 206 and the sterilization of surgical instruments. Surgical instruments and surgical material were contaminated with difficult to kill organisms at levels up to 10,000x. This presented significant sterilizing challenges, including challenges with bacterial spores. Following a 20-minute soak in Ygiene 206, the instruments were sterile. "I contaminated the surgical instruments and other material with very high levels of dangerous organisms (10/10th), letting the contaminants bind to the instruments for two hours. Without removal of any of the microorganisms, the instruments were placed in a tray for a 20 minute soak with direct contact to Ygiene 206. After which time I was able to determine that the instruments were indeed, sterile. Along with its compatibility with surgical stainless steel and other materials and surfaces, these tests show that Ygiene 206 would be an excellent pre-soak for contaminated surgical instruments," said Dr. Philip Tierno.

Nationally, there are over 40 million surgical cases a year resulting in highly contaminated surgical instruments. On Subsequently, on October 2, 2012 in conjunction with Company's announcement, Barnabas Health issued a White Paper describing the Research Program and its results. Exposures to blood and/or body fluids from used surgical instruments continue to occur on a daily basis. Other than engineering and work practice controls, there is little else available to protect healthcare workers responsible for cleaning used instruments. This Research Program was performed to determine the feasibility of using a disinfectant/sterilant chemical as a pre-treatment for used surgical instruments to protect healthcare workers from exposure to blood and/or body fluids when processing contaminated surgical instruments. The Research Program included using the chemical in a variety of settings including exposure to human blood that had dried for twelve (12) hours. The results of the Research Program confirm that the Ygiene 206 chemical may be used to disinfect surgical instruments as a precursor to cleaning and prior to terminal sterilization. In this Research Program of about fifty (50) surgical instruments conducted at Saint Barnabas Medical Center, a Barnabas Health facility, Ygiene 206 Sterilant was shown to effectively remove microorganisms in the presence of blood from contaminated surgical instruments in 90 seconds to two minutes. In this controlled and limited study, Ygiene 206 was effective as a disinfectant in the presence of blood on surgical instruments even when the surgical instruments were grossly soiled and remained in the closed position.

v/r
Sterling